Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following is a list of abstracts that will be presented at the meeting.
Scientific Poster Presentations
Poster Number & Category |
Title & Presenter |
Day & Time |
||
29 Biomarkers, Immune Monitoring, and Novel Technologies |
Profiling Tumor Circulating Cell-Free DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of Somatic Mutations Presenter: |
|
||
57 Biomarkers, Immune Monitoring, and Novel Technologies |
Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets Presenter: |
|
||
67 Biomarkers, Immune Monitoring, and Novel Technologies |
B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Presenter: |
|
||
73 Biomarkers, Immune Monitoring, and Novel Technologies |
Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity Presenter: |
|
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Industry Sponsor Symposium
Presentation Category |
Title & Presenter |
Day & Time |
||
Sponsored Symposia |
Maximizing immunotherapy biomarker discovery with a multidimensional tumor immunogenomics platform Presenter: |
|
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109006091/en/
Investor Relations Contact:
investors@personalis.com
415-202-5678
Media Contact:
pr@personalis.com
www.personalis.com
650-752-1300
Source: